Indication
Central Nervous System Tumor
18 clinical trials
16 products
7 drugs
Product
avapritinibProduct
InfigratinibClinical trial
A Phase 1/2, Single-arm Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA SignalingStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase 1b/2, Multicenter, Open-Label Study of Oral Infigratinib in Pediatric Subjects With Advanced Solid and Central Nervous System (CNS) Tumors (Phase 1b) and in Subjects With Recurrent or Progressive Low-Grade Gliomas Harboring Selected FGFR1, FGFR2, or FGFR3 Alterations (Phase 2)Status: Withdrawn, Estimated PCD: 2022-12-16
Clinical trial
Molecularly-Driven Doublet Therapy for All Children With Refractory or Recurrent CNS Malignant Neoplasms and Young Adults With Refractory or Recurrent SHH MedulloblastomaStatus: Completed, Estimated PCD: 2022-09-30
Drug
GemcitabineClinical trial
Phase 1 Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System TumorsStatus: Recruiting, Estimated PCD: 2028-01-15
Product
SC-CAR4BRAINClinical trial
Phase 1 Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System TumorsStatus: Recruiting, Estimated PCD: 2026-05-01
Product
SCRI-CARB7H3Clinical trial
PNOC023: Open Label Phase 1 and Target Validation Study of ONC206 in Children and Young Adults With Newly Diagnosed or Recurrent Diffuse Midline Glioma (DMG), and Other Recurrent Primary Malignant Central Nervous System (CNS) TumorsStatus: Recruiting, Estimated PCD: 2026-01-31
Drug
ONC206Drug
ribociclibProduct
sonidegibClinical trial
Phase 1 Study of HER2-Specific CAR T Cell Locoregional Immunotherapy for HER2 Positive Recurrent/Refractory Pediatric Central Nervous System TumorsStatus: Active (not recruiting), Estimated PCD: 2024-07-26
Drug
trametinibDrug
FilgrastimClinical trial
Phase 1 Study of EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric Central Nervous System TumorsStatus: Active (not recruiting), Estimated PCD: 2025-03-01
Clinical trial
Mapping Draining Lymph Nodes in CNS MalignanciesStatus: Terminated, Estimated PCD: 2022-04-30
Product
Tc-99m tilmanoceptClinical trial
A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in ChildrenStatus: Completed, Estimated PCD: 2015-04-09
Product
Sodium ThiosulfateClinical trial
A Phase 2 Study of Fluorescence Detection of Adult Primary Central Nervous System Tumors in Subjects Receiving Tozuleristide and Imaged With the Canvas SystemStatus: Recruiting, Estimated PCD: 2024-11-01
Product
tozuleristideClinical trial
A Multi-Center Phase I Dose Escalation Study of Avutometinib, a RAF/MEK Clamp, in Pediatric Patients With Refractory or Recurrent Solid Tumors Harboring Activating MAPK Pathway AlterationsStatus: Recruiting, Estimated PCD: 2029-10-20
Drug
AvutometinibClinical trial
Preventative Skin Care for Children Undergoing Targeted CNS Tumor TherapyStatus: Active (not recruiting), Estimated PCD: 2024-01-01
Product
SPF 30 or Higher SuncreenClinical trial
A Phase I/II Study of Neratinib in Pediatric Patients With Relapsed or Refractory Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-10-01
Product
NeratinibProduct
L-(11C) MethionineClinical trial
iSTAR: Phase 1b Trial of Idasanutlin and Selinexor Therapy For Children With Progressive/Relapsed Atypical Teratoid Rhabdoid Tumors, Extra-CNS Malignant Rhabdoid Tumors Or Synchronous/Metachronous Rhabdoid TumorsStatus: Withdrawn, Estimated PCD: 2025-09-01
Product
IdasanutlinDrug
SelinexorClinical trial
A Multicenter, Open-label, Interventional Phase I Trial to Determine the Dose and Evaluate the Pharmacokinetics (PK) and Safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as Monotherapy or Following Standard of Care (SoC) for the Treatment of Somatostatin Receptor-positive Tumors in the Pediatric Population (KinLET).Status: Not yet recruiting, Estimated PCD: 2028-06-01
Product
Lutetium Lu 177-EdotreotideClinical trial
INFORM2 Exploratory Multinational Phase I/II Combination Study of Nivolumab and Entinostat in Children and Adolescents With Refractory High-risk Malignancies (INFORM2-NivEnt)Status: Recruiting, Estimated PCD: 2026-06-30
Product
Nivolumab + Entinostat